Hepatitis E virus drug development

  • Hepatitis E virus (HEV) is an underestimated disease, leading to estimated 20 million infections and up to 70,000 deaths annually. Infections are mostly asymptomatic but can reach mortality rates up to 25% in pregnant women or become chronic in immunocompromised patients. The current therapy options are limited to the unspecific antivirals Ribavirin (RBV) and pegylated Interferon-\(\alpha\) (pegIFN-\(\alpha\)). RBV leads to viral clearance in only 80% of patients treated, and is, similar to pegIFN-\(\alpha\), contraindicated in the major risk group of pregnant women, emphasizing the importance of new therapy options. In this review, we focus on the urgent need and current efforts in HEV drug development. We provide an overview of the current status of HEV antiviral research. Furthermore, we discuss strategies for drug development and the limitations of the approaches with respect to HEV.

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar
Metadaten
Author:Volker KinastORCiDGND, Thomas BurkardORCiDGND, Daniel Matthias TodtORCiDGND, Eike SteinmannORCiDGND
URN:urn:nbn:de:hbz:294-67684
DOI:https://doi.org/10.3390/v11060485
Parent Title (English):Viruses
Publisher:MDPI
Place of publication:Basel
Document Type:Article
Language:English
Date of Publication (online):2019/11/28
Date of first Publication:2019/05/28
Publishing Institution:Ruhr-Universität Bochum, Universitätsbibliothek
Tag:Open Access Fonds
antivirals; drug development; hepatitis E virus; ribavirin; sofosbuvir; therapy; vaccine
Volume:11
Issue:6
First Page:485-1
Last Page:485-16
Note:
Article Processing Charge funded by the Deutsche Forschungsgemeinschaft (DFG) and the Open Access Publication Fund of Ruhr-Universität Bochum.
Institutes/Facilities:Institut für Hygiene und Mikrobiologie, Abteilung für Molekulare und Medizinische Virologie
open_access (DINI-Set):open_access
faculties:Medizinische Fakultät
Licence (English):License LogoCreative Commons - CC BY 4.0 - Attribution 4.0 International